Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

Published:2016-05-10 Issue:15 Volume:122 Page:2371-2378
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Belani Chandra P.¹,Dahlberg Suzanne E.²,Rudin Charles M.³,Fleisher Martin⁴,Chen Helen X.⁵,Takebe Naoko⁵,Velasco Mario R.⁶,Tester William J.⁷,Sturtz Keren⁸,Hann Christine L.³,Shanks James C.⁹,Monga Manish¹⁰,Ramalingam Suresh S.¹¹,Schiller Joan H.¹²

Affiliation:

1. Penn State Hershey Cancer Institute; Hershey Pennsylvania

2. ECOG-ACRIN Biostatistics Center; Dana-Farber Cancer Institute; Boston Massachusetts

3. Johns Hopkins University; Baltimore Maryland

4. Memorial Sloan Kettering Cancer Center; New York New York

5. National Cancer Institute; Rockville Maryland

6. Decatur Memorial Hospital; Decatur Illinois

7. Albert Einstein Cancer Center; Philadelphia Pennsylvania

8. Colorado Cancer Research Program; Denver Colorado

9. HealthEast Cancer Care; Maplewood Minnesota

10. West Virginia University; Morgantown West Virginia

11. Emory University; Atlanta Georgia

12. University of Texas Southwestern Medical Center; Dallas Texas

Funder

National Cancer Institute (National Institutes of Health, Department of Health and Human Services)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference18 articles.

1. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database;Govindan;J Clin Oncol.,2006

2. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress;Chute;J Clin Oncol.,1999

3. Cancer stem cells and the ontogeny of lung cancer;Peacock;J Clin Oncol.,2008

4. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer;Watkins;Nature.,2003

5. Targeting the hedgehog pathway in cancer;Rubin;Nat Rev Drug Discov.,2006

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating tumor cells with increasing aneuploidy predict inferior prognosis and therapeutic resistance in small cell lung cancer;Drug Resistance Updates;2024-09

2. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer;Advanced Science;2024-08-13

3. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer;Nature Reviews Clinical Oncology;2024-07-04

4. Role of DNA Damage Response in Cancer and Healthy Stem Cells: Genome Stability, Tumor Development and Drug Resistance;Comprehensive Hematology and Stem Cell Research;2024

5. Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy;Cancer Treatment Reviews;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3